pause_circle_filledNot Yet Recruiting

Stable coronary artery disease

Bayer Identifier:
22597
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
EU CT Number:
Not Available
A study to learn about how safe nitroglycerin is and how it affects the body when taken along with nurandociguat in people with coronary artery disease

Trial purpose

This study is designed to find out how safe nitroglycerin is and how it affects the body when it is taken together with another medicine called nurandociguat in people who have coronary artery disease (CAD). CAD is a condition where the arteries that supply blood to the heart become narrowed or blocked, often causing chest pain or even heart attacks. Many people with CAD also have chronic kidney disease (CKD), a long-term condition where the kidneys do not work as well as they should.

People with CAD often use nitroglycerin to help improve blood flow to the heart. Nurandociguat is a new medicine being studied to help people with CKD by widening blood vessels and improving blood flow. Both nitroglycerin and nurandociguat work in similar ways in the body, so taking them together could have a stronger effect on blood vessels. This might lead to a sudden drop in blood pressure or other side effects. The main goal of this study is to learn how safe it is to use nitroglycerin and nurandociguat together, and to understand how they interact in the body.

Key Participants Requirements

Sex

All

Age

40 - 80 Years
    • Participant must be 40 to 80 years of age inclusive at the time of signing the informed consent
    • Participants with stable CAD defined by coronary artery stenosis in any of the 3 main coronary vessels greater than 50 percent documented by coronary angiography within the last 36 months or history of myocardial infarction more than 6 months prior to the screening visit
    • Estimated glomerular filtration rate (eGFR) greater than or equal to 30 mL per min per 1.73 m2 at screening
    • Body weight greater than or equal to 60 kg and body mass index within the range greater than or equal to 18 and less than or equal to 36 kg per m2 at screening.
    • Ejection fraction less than 30 percent at screening as determined by echocardiography
    • Progressive angina with symptoms of worsening of angina in the 3 months prior to the first screening examination and/or interventions such as revascularization by percutaneous coronary intervention and or coronary artery bypass graft during the last 3 months
    • Documented current relevant coronary stenosis greater than or equal to 90 percent in any of the main 3 coronary vessels without bypass graft
    • Significant valvular heart disease with moderate or severe aortic stenosis or any other significant stenosis any other moderate or severe valvular failures hypertrophic obstructive cardiomyopathy
    • Symptomatic carotid stenosis or transient ischemic attack or stroke within 3 months prior to the first screening examination or patients with stroke at more than 3 months prior to the first screening examination with significant residual neurologic involvement
    • Atrial fibrillation pacemaker defibrillator atrial ventricular block II and III
    • History of sustained ventricular tachycardia or ventricular fibrillation within 12 months prior first screening visit
    • History of CNS diseases such as seizures neurodegenerative diseases
    • Lung diseases such as COPD GOLD stage 2-4 pulmonary arterial hypertension or asthma
    • Medical disorder condition or history of such that would impair the participant's ability to participate or complete the study in the opinion of the investigator.

Trial summary

Enrollment Goal
36
Trial Dates
March 2026 - October 2026
Phase
Phase 1
Could I Receive a placebo
Yes
Products
Nurandociguat, BAY 3283142
Accepts Healthy Volunteer
false

Where to participate

StatusInstitutionLocation
Not Yet Recruiting
UK Bonn Institut für Klinische Chemie und Klinische Pharmakologie, Phase I Einheit und ArzneimitteltherapiesicherheitBonn, 53127, Germany
Not Yet Recruiting
Universitätsklinikum Heidelberg - Zentrum für Innere Medizin, Abteilung Klinische Pharmakologie und PharmakoepidemologieHeidelberg, 69120, Germany
Not Yet Recruiting
Deutsches Herzzentrum der Charité (DHZC) - Klinik für Kardiologie, Angiologie und Intensivmedizin CVKBerlin, 13353, Germany
Not Yet Recruiting
SocraTec R&D Erfurt-Clinical Pharmacology UnitErfurt, 99084, Germany
Not Yet Recruiting
Comac Medical | Phase I Clinical Research UnitSofia, 1000, Bulgaria

Primary Outcome

  • Number of participants with treatment-emergent adverse events per treatment group
    The incidence of treatment-emergent adverse events will be summarized.
    date_rangeTime Frame:
    Up to 7 days after the last treatment, for a total of up to about 7 weeks per participant

Trial design

A randomized, placebo-controlled, single blind drug-drug interaction study to investigate the influence of 0.4 mg nitroglycerin spray on the safety, tolerability and pharmacodynamic effects of nurandociguat in participants with stable coronary artery disease.
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
Randomized
Blinding
Single-blind
Assignment
Parallel
Trial Arms
2

Additional Information

Click here for access to information about Bayer’s transparency standards and Bayer studies.